Twist Bioscience Corporation (TWST) Guidance & Earnings Results
On 2026-08-03 Twist Bioscience Corporation raised guidance: "FY2026 revenue guidance raised to $456-457M from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TWSTTwist Bioscience CorporationFollow TWST — free
—
Price chart with a free account
- Market cap
- 8.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 13 Nov, in 20 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 3 Aug 26 | Raised | FY2026 revenue guidance raised to $456-457M from $442-447M · full year |
| 4 May 26 | Raised | FY26 revenue guidance raised from $435-440M to $442-447M · full year |
| 2 Feb 26 | Raised | Revenue guidance raised from $425-435M to $435-440M · full year |
| 14 Nov 25 | Raised | FY2026 revenue guidance $425M-$435M (13-15.5% YoY growth); gross margin above 52%; Q4 FY2026 adjusted EBITDA breakeven. |
| 4 Aug 25 | Mixed | FY25 revenue $374-376M (prev $372-379M); FY25 gross margin 50.5-51% (prev 49.5%); FY25 adjusted EBITDA $(45-47)M (prev $(48-53)M); Q4 revenue $96-98M; Q4 gross margin 51-52%; Q4 adjusted EBITDA $(6-8)M; FY26 adjusted EBITDA breakeven · full year |
Twist Bioscience Corporation — questions
- What guidance did Twist Bioscience Corporation give?
- On 2026-08-03: "FY2026 revenue guidance raised to $456-457M from $442-447M"
- When does Twist Bioscience Corporation report earnings?
- Twist Bioscience Corporation's next earnings report is expected on 2026-11-13.
Every figure on this page comes from Twist Bioscience Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.